ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1329

Investigating Predictors of Transfusion in Rheumatoid Arthritis and Osteoarthritis Patients Undergoing Knee Arthroplasty

Stephen Batter1, Huong Do1, Dongmei Sun2, Ahmed Deeb1, Trang Bui1, Jason Blevins1, Mark Figgie1, Gwo-Chin Lee1, J. Alex B. Gibbons3, Bella Mehta4, Susan Goodman5 and Linda A Russell1, 1Hospital for Special Surgery, New York, NY, 2Hospital for Special Surgery, Birmingham, AL, 3Columbia University Vagelos College of Physicians & Surgeons, New York, NY, 4Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, 5Hospital for Special Surgery, New York 10025, NY

Meeting: ACR Convergence 2024

Keywords: rheumatoid arthritis, risk assessment

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 17, 2024

Title: RA – Diagnosis, Manifestations, & Outcomes Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Use of ambulatory surgery in arthroplasty is increasing, but the need for transfusion mandates hospital admission. Despite the significant drop in transfusion rate linked to antifibrinolytic therapy, a significant number of patients are still transfused. Few prior studies have assessed primary rheumatologic diagnosis- such as rheumatoid arthritis- as a risk factor for the need for transfusion. The purpose of this study is to determine preoperative factors associated with receiving a blood transfusion after total knee arthroplasty (TKA) to optimally use ambulatory surgery, and to determine whether RA patients experience higher rates of transfusion.

Methods: We retrospectively reviewed primary unilateral TKA patients from a single tertiary care institution from February 2016 to December 2022. Patient demographics, preoperative hemoglobin, BMI, diagnosis of RA, and tranexamic acid (TXA) use were obtained from the hospital electronic medical record. RA status was identified by ICD-10-CM diagnosis codes for RA or JIA (M05.x, M06.0x, M06.2x, M06.3x, M06.8x, M06.9x, M08.0x, M08.2x, M08.3x, M08.4x). The association of these variables with the primary outcome of receiving a packed red blood cell (RBC) transfusion was evaluated using the chi-square test or Fisher’s Exact Test, as appropriate, and in a multivariable logistic regression model.

Results: There were 29,092 TKA included; 2.8% (822) received transfusions. Mean age was 67.1 years, mean preoperative hemoglobin was 13.5 g/dL, and 61.2% were female. 62.7% of patients had a Charlson Comorbidity score of 0 and 4.0% had a diagnosis of rheumatoid arthritis. Transfusion rate declined over the study period from 5.7% in 2016 to 0.9% in 2022. Risk factors for transfusion included male sex (odds ratio (OR) 1.52, 95% confidence interval (CI): 1.27, 1.82) and higher Charlson Comorbidity index (1 vs 0: OR 1.53, 95% CI: 1.26, 1.85 and 2+ vs 0: OR 1.86, 95% CI: 1.52, 2.27). Each 1 g/dL increase in preoperative hemoglobin decreased the risk of transfusion (OR 0.34, 95% CI: 0.32, 0.36). No TXA use increased the risk of transfusion (OR 5.03, 95% CI: 4.26, 5.95). Diagnosis of RA was not a significant risk factor for transfusion as compared to the general population. (OR 1.03, 95% CI: 0.79, 1.40).

Conclusion: Higher preoperative hemoglobin and use of TXA decreased the likelihood of having a transfusion, while male sex and higher comorbidity burden increased the risk of transfusion. RA was not a significant risk factor for transfusion. Significant preoperative factors should be assessed in patients being considered for ambulatory TKR to reduce the need for subsequent admission and transfusion. Future analysis should determine the optimal hemoglobin cut-off to avoid admission for transfusion.

Supporting image 1

Supporting image 2

Figure 1: Number of total knee arthroplasties and transfusion rate by year

Supporting image 3

Figure 2: Odds Ratios from Multivariable Logistic Regression Model of Transfusion Risk


Disclosures: S. Batter: None; H. Do: None; D. Sun: None; A. Deeb: None; T. Bui: None; J. Blevins: Globus Medical, 2, Lima Corporate, 2, Smith and Nephew, 2; M. Figgie: HS2, 11, Icarus, 11, Joint Effort ASO, 11, Lima, 2, 9, Mekanika, 11, Wishbone, 2, 4, 10; G. Lee: Corin USA, 2; J. Gibbons: None; B. Mehta: None; S. Goodman: Novartis Corporation Pharmaceuticals, 5, UCB, 1; L. A Russell: None.

To cite this abstract in AMA style:

Batter S, Do H, Sun D, Deeb A, Bui T, Blevins J, Figgie M, Lee G, Gibbons J, Mehta B, Goodman S, A Russell L. Investigating Predictors of Transfusion in Rheumatoid Arthritis and Osteoarthritis Patients Undergoing Knee Arthroplasty [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/investigating-predictors-of-transfusion-in-rheumatoid-arthritis-and-osteoarthritis-patients-undergoing-knee-arthroplasty/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/investigating-predictors-of-transfusion-in-rheumatoid-arthritis-and-osteoarthritis-patients-undergoing-knee-arthroplasty/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology